| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on September 8, 2005
Accepted on December 13, 2005
Article |
1 Department of Nuclear Medicine, St. Vincent's University Hospital; UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin; and Dublin Molecular Medicine Institute, Dublin, Ireland
Background: Although multiple serum-based tumor markers have been described for breast cancer, such as CA 15-3, BR 27.29 (CA27.29), carcinoembryonic antigen, tissue polypeptide antigen, tissue polypeptide specific antigen, and HER-2 (the extracellular domain), the most widely used are CA 15-3 and CEA.
Methods: The literature relevant to serum tumor markers in breast cancer was reviewed. Particular attention was given to systematic reviews, prospective randomized trials, and guidelines issued by expert panels.
Results: Because of a lack of sensitivity for early disease and lack of specificity, none of the available markers are of value for the detection of early breast cancer. High preoperative concentrations of CA 15-3 are, however, associated with adverse patient outcome. Although serial determinations of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of 
2-9 months, the clinical value of this lead time remains to be determined. Serum markers, however, are the only validated approach for monitoring treatment in patients with advanced disease that cannot be evaluated by use of conventional criteria.
Conclusions: CA 15-3 is one of the first circulating prognostic factors for breast cancer. Preoperative concentrations thus might be combined with existing prognostic factors for predicting outcome in patients with newly diagnosed breast cancer. At present, the most important clinical application of CA 15-3 is in monitoring therapy in patients with advanced breast cancer that is not assessable by existing clinical or radiologic procedures.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  Y. H. Seo and K. S. Carroll Profiling protein thiol oxidation in tumor cells using sulfenic acid-specific antibodies PNAS, September 22, 2009; 106(38): 16163 - 16168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Desmetz, C. Bascoul-Mollevi, P. Rochaix, P.-J. Lamy, A. Kramar, P. Rouanet, T. Maudelonde, A. Mange, and J. Solassol Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women Clin. Cancer Res., July 15, 2009; 15(14): 4733 - 4741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. DIVELLA, S. TOMMASI, R. LACALAMITA, A. DANIELE, I. ABBATE, V. M. GARRISI, E. SAVINO, M. COVIELLO, V. RUBINI, G. SIMONE, et al. Circulating hTERT DNA in Early Breast Cancer Anticancer Res, July 1, 2009; 29(7): 2845 - 2849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. M Abd Hamid, L. Royle, R. Saldova, C. M Radcliffe, D. J Harvey, S. J Storr, M. Pardo, R. Antrobus, C. J Chapman, N. Zitzmann, et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression Glycobiology, December 1, 2008; 18(12): 1105 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Duffy and J. Crown A Personalized Approach to Cancer Treatment: How Biomarkers Can Help Clin. Chem., November 1, 2008; 54(11): 1770 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Kyselova, Y. Mechref, P. Kang, J. A. Goetz, L. E. Dobrolecki, G. W. Sledge, L. Schnaper, R. J. Hickey, L. H. Malkas, and M. V. Novotny Breast Cancer Diagnosis and Prognosis through Quantitative Measurements of Serum Glycan Profiles Clin. Chem., July 1, 2008; 54(7): 1166 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-W. Park, J.-W. Oh, J.-H. Kim, S. H. Park, K.-S. Kim, J. H. Kim, and K. S. Lee Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes Ann. Onc., April 1, 2008; 19(4): 675 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tang, R. Yuan, and Y. Chai Magnetic Control of an Electrochemical Microfluidic Device with an Arrayed Immunosensor for Simultaneous Multiple Immunoassays Clin. Chem., July 1, 2007; 53(7): 1323 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kirmiz, B. Li, H. J. An, B. H. Clowers, H. K. Chew, K. S. Lam, A. Ferrige, R. Alecio, A. D. Borowsky, S. Sulaimon, et al. A Serum Glycomics Approach to Breast Cancer Biomarkers Mol. Cell. Proteomics, January 1, 2007; 6(1): 43 - 55. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
